Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04841629 · ClinicalTrials.gov registry record · NA

Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device

A NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System, sponsored by Glyciome.

Completed
Registry status
NA
Development phase
42
Enrollment target
2
Study locations

NCT04841629 is a NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System that has completed, run by Glyciome. The registered enrollment target is 42 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04841629, a NA study of Sensory Perceptual Characteristics and User Acceptability of Gel Delivery System, has completed, sponsored by Glyciome.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target
2
Study locations

Study Summary

PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applicator design will be evaluated for: look and feel, ability to prepare for dosing, ability to expulse dose, and likelihood of future use by subjects. Open-ended feedback on the gel and applicator will occur to gather contributions for each product.

Interventions

  • OTHER PreBioGyn Gel
  • OTHER Trimosan Gel
  • OTHER RepHresh Gel

Study Locations (2)

Massachusetts

  • Brigham and Women'S Hospital - Boston

Other

  • University of Puerto Rico Medical Sciences - San Juan

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2022-02-24
Est. Completion 2022-11-28
Phase NA

Sponsor

Glyciome

1 total trials

What the Registry Record Tells You About NCT04841629

The ClinicalTrials.gov registry entry for NCT04841629 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glyciome, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sensory Perceptual Characteristics appearing as the primary indexed condition, and to 3 interventions - of which PreBioGyn Gel is the first listed.

NCT04841629 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Other.

Frequently Asked Questions

What is clinical trial NCT04841629 about?

NCT04841629 is a clinical study titled "Perception & Acceptability of a Cervical Cancer Prevention Prebiotic Device". PreBioGyn will be compared to market leading vaginal pH buffering gels using established forearm test methods associated with vaginal lubricity sensation in 42 women. Women will also rate each gel for smell and appearance using established methods. The PreBioGyn gel enclosure and intravaginal applic...

What is the current status of trial NCT04841629?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2022-02-24. Estimated completion is 2022-11-28.

What conditions does trial NCT04841629 study?

This clinical trial studies the following conditions: Sensory Perceptual Characteristics, User Acceptability of Gel Delivery System.

What interventions are being tested in trial NCT04841629?

The interventions under investigation include: PreBioGyn Gel (OTHER), Trimosan Gel (OTHER), RepHresh Gel (OTHER).

Who is sponsoring clinical trial NCT04841629?

This trial is sponsored by Glyciome, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04841629 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.